Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study

Published:2016 Issue:4 Volume:8 Page:319
ISSN:2092-7355
Container-title:Allergy, Asthma & Immunology Research
language:en
Short-container-title:Allergy Asthma Immunol Res

Author:

Li Jing¹,Kang Jian²,Wang Changzheng³,Yang Jing⁴,Wang Linda⁵,Kottakis Ioannis⁶,Humphries Michael⁴,Zhong Nanshan¹,

Affiliation:

1. State Key Laboratory of Respiratory Disease, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.

2. Institute of Respiratory Disease, First Hospital of China Medical University, Shenyang, China.

3. Institute of Respiratory Disease, Xinqiao Hospital, Third Military Medical University, Chongqing, China.

4. Respiratory Franchise, Beijing Novartis Pharma Co. Ltd., Beijing, China.

5. IQS, Beijing Novartis Pharma Co. Ltd., Shanghai, China.

6. Novartis Pharma AG, Basel, Switzerland.

Funder

Novartis Pharma AG

Publisher

The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al

Subject

Pulmonary and Respiratory Medicine,Immunology,Immunology and Allergy

Link

http://synapse.koreamed.org/pdf/10.4168/aair.2016.8.4.319

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity of biologics used in the treatment of asthma;Human Antibodies;2024-07-24

2. Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials;European Respiratory Review;2024-04-24

3. Effects of omalizumab on lung function in patients with moderate-to-severe allergic asthma: a systematic review and meta-analysis;Therapeutic Advances in Respiratory Disease;2024-01

4. A Randomized, Single‐Dose, Parallel‐Controlled Phase I Clinical Comparison of an Omalizumab Biosimilar Candidate with Reference Omalizumab in Healthy Chinese Male Volunteers;Clinical Pharmacology in Drug Development;2023-12-06

5. Comparing bronchial thermoplasty with biologicals for severe asthma: Systematic review and network meta-analysis;Respiratory Medicine;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3